|
|
Article: Clinic Roundup.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
o 4SC AG, of Planegg-Martinsried, Germany, has completed patient recruitment for the Phase IIa clinical trial with its drug candidate SC12267 for the treatment of rheumatoid arthritis. In the three-tiered and placebo-controlled study, patients will be given two doses of SC12267 per day over a three-month period and tested for tolerance and clinical efficacy. The study is being carried out in 13 centers in Germany, Poland and Serbia. Results are expected for the fourth quarter of 2007.
o Aastrom Biosciences Inc., of Ann Arbor, Mich., said the first critical limb ischemia patient was treated in its Phase IIb trial of its Vascular Repair Cell product. The ...